Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product (Q43113924)

14 November 2017

title

Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product (English)

1 reference

14 November 2017

1

Mario Thevis

1 reference

14 November 2017

4

Wilhelm Schänzer

1 reference

14 November 2017

3

Matthias Kamber

1 reference

14 November 2017

Hans Geyer

2

1 reference

14 November 2017

publication date

1 August 2009

1 reference

Drug Testing and Analysis

14 November 2017

published in

1 reference

14 November 2017

volume

1

1 reference

14 November 2017

issue

8

1 reference

14 November 2017

page(s)

387-392

1 reference

Discovery of nonsteroidal androgens

14 November 2017

cites work

1 reference

7 January 2021

Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium

1 reference

7 January 2021

Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential

1 reference

7 January 2021

Selective androgen receptor modulators as function promoting therapies

1 reference

7 January 2021

Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit

1 reference

7 January 2021

Screening for two selective androgen receptor modulators using gas chromatography-mass spectrometry in doping control analysis

1 reference

7 January 2021

Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes

1 reference

7 January 2021

Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis

1 reference

7 January 2021

Mass spectrometry of hydantoin-derived selective androgen receptor modulators

1 reference

7 January 2021

Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS.

1 reference

7 January 2021

Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry

1 reference

7 January 2021

Use of an electrochemically synthesised metabolite of a selective androgen receptor modulator for mass spectrometry-based sports drug testing

1 reference

7 January 2021

Mass spectrometry of selective androgen receptor modulators

1 reference

7 January 2021

Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators

1 reference

7 January 2021

Resolution of the non steroidal antiandrogen 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide and the determination of the absolute configuration of the active enantiomer

1 reference

7 January 2021

Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides

1 reference

7 January 2021

Characterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparations

1 reference

7 January 2021

Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator

1 reference

7 January 2021

The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators

1 reference

7 January 2021

In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.

1 reference

7 January 2021

Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study

1 reference

7 January 2021

Identifiers

DOI

10.1002/DTA.91

1 reference

14 November 2017

1 reference